-

DMS Imaging: Information on the Total Number of Voting Rights and Shares

(in compliance with the dispositions of the law of May 2nd, 2007)

BRUSSELS--(BUSINESS WIRE)--Regulatory News:

DMS Imaging (formerly ASIT Biotech) (DMSIM - BE0974289218) (BSE:DMSIM) (Paris:DMSIM) publishes today the information in compliance with article 15 of the Belgian law of May 2nd, 2007, regarding the publication of major shareholdings.

Information on February 28th, 2022:

  • Total amount of social capital: 66 071 856.50 €
  • Total number of securities giving a Unique Voting Right: 1 489 607 331
  • Total number of outstanding common shares: 1 489 607 331
  • Total number of voting rights: 1 489 607 331

***

About DMS Imaging

Specialized in high technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

DMS Imaging is quoted on the Paris Euronext Market (ISIN: BE0974289218 - memo: DMSIM).

More information on https://www.asitbiotech.com/fr/.

Contacts

DMS Imaging

Samuel SANCERNI
General director
+33 4 67 50 49 00

Delphine de COURSON
Chief Financial Officer
+33 4 67 50 49 00

DMS Imaging

BOURSE:DMSIM
Release Versions
EnglishFrench

Contacts

DMS Imaging

Samuel SANCERNI
General director
+33 4 67 50 49 00

Delphine de COURSON
Chief Financial Officer
+33 4 67 50 49 00

More News From DMS Imaging

DMS Imaging: Publication Regarding a Transparency Notification

BRUSSELS--(BUSINESS WIRE)--Regulatory News: DMS Imaging (formerly ASIT Biotech) (DMSIM - BE0974289218) (BSE:DMSIM) (Paris:DMSIM), announces today the receiving of a transparency notification from February 25th, 2022, resulting in an increase of capital on January 24th, 2022, within the framework of the contribution in kind of the medical imaging division of Diagnostic Medical Systems to the Company, Diagnostic Medical Systems now holds 88.33% of the Company’s voting rights and crosses the 85% t...

ASIT biotech Presents Its 2020 Half Year Results and Provides a Business Update Until End 2020

BRUSSELS--(BUSINESS WIRE)--Regulatory News: ASIT biotech (ASIT - BE0974289218) (BSE:ASIT) (Paris:ASIT), a biopharmaceutical company focused on the research, development and future commercialization of breakthrough allergy immunotherapy products, today announces its 2020 half-year results1, and provides a business update. The Company continues to minimize its expenses. As of June 30, 2020, the Company had a cash position of €2.9 million. The Company continues its efforts to valorize its assets....

ASIT biotech Obtains the Benefit of the Judicial Reorganization by Collective Agreement

BRUSSELS--(BUSINESS WIRE)--Regulatory News: ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research and development of breakthrough immunotherapy, obtains the benefit of the judicial reorganization by collective agreement in execution of the judgment delivered on February 11, 2020 by the Commercial Court of Liège1 in application of the law of August 11, 2017 inserting Book XX "Insolvency of Enterprises" in the Code of econom...
Back to Newsroom